[Outcomes of HIFU for localised prostate cancer using the Ablatherm Integrate Imaging® device].

[1]  Alexandre Mamedov,et al.  Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Eastham,et al.  High‐intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure , 2009, BJU international.

[3]  F. García-Vicente,et al.  Post-treatment prostate biopsies in the era of three-dimensional conformal radiotherapy: what can they teach us? , 2009, European urology.

[4]  L. Holmberg,et al.  Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. , 2008, Journal of the National Cancer Institute.

[5]  S. Pichardo,et al.  New integrated imaging high intensity focused ultrasound probe for transrectal prostate cancer treatment. , 2008, Ultrasound in medicine & biology.

[6]  F. Murat,et al.  Adénocarcinome prostatique en récidive locale après radiothérapie exclusive : résultats du traitement par ultrasons focalisés , 2008 .

[7]  Victor E Reuter,et al.  Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer. , 2008, The Journal of urology.

[8]  John T. Wei,et al.  Quality of life and satisfaction with outcome among prostate-cancer survivors. , 2008, The New England journal of medicine.

[9]  M. Schostak,et al.  PSA nadir is a significant predictor of treatment failure after high-intensity focussed ultrasound (HIFU) treatment of localised prostate cancer. , 2008, European urology.

[10]  A. Gelet,et al.  Salvage radiotherapy after high-intensity focused ultrasound for localized prostate cancer: early clinical results. , 2007, Urology.

[11]  Lei Dong,et al.  Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. , 2008, International journal of radiation oncology, biology, physics.

[12]  Rainer Hofmann,et al.  Complications of transurethral resection of the prostate (TURP)--incidence, management, and prevention. , 2006, European urology.

[13]  M. Emberton,et al.  To what extent does the prostate‐specific antigen nadir predict subsequent treatment failure after transrectal high‐intensity focused ultrasound therapy for presumed localized adenocarcinoma of the prostate? , 2006, BJU international.

[14]  P. Wild,et al.  Morbidity associated with repeated transrectal high-intensity focused ultrasound treatment of localized prostate cancer , 2006, World Journal of Urology.

[15]  Guy Vallancien,et al.  Transrectal focused ultrasound combined with transurethral resection of the prostate for the treatment of localized prostate cancer: feasibility study. , 2004, The Journal of urology.

[16]  A. Hanlon,et al.  Radiation therapy dose escalation for prostate cancer: a rationale for IMRT , 2003, World Journal of Urology.

[17]  C. Chaussy,et al.  The status of high-intensity focused ultrasound in the treatment of localized prostate cancer and the impact of a combined resection , 2003, Current urology reports.

[18]  D. Kuban,et al.  Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial. , 2002, International journal of radiation oncology, biology, physics.